TYVASO® (treprostinil)
Behind you all the way.
When you prescribe TYVASO, United Therapeutics Cares is there to support what comes next. From initiating benefits investigations to coordinating prescriptions and providing ongoing patient education, our Patient Navigators and our full team of specialists help support your patients so they can focus on what matters.
Enroll a patient
Prescribe and help enroll your patient in support.
Referral form
Work with your patient to complete the referral form and fax it to 1‑800‑380‑5294.
Download referral form Download referral form (Spanish)e-Prescribe
Submit prescriptions through your existing electronic health record (EHR) workflow.
- Submit the prescription through your eRx workflow.
- Select United Therapeutics Pharmacy Services™ as the pharmacy (NPI #1124944871).
- UTPS will transfer to a Specialty Pharmacy based on payer preference or your preference.
Prescribing and enrollment resources
These resources can help with the getting started process.
-
TYVASO/TYVASO DPI hospital-to-home referral form
-
TYVASO/TYVASO DPI Veterans Affairs referral form
-
TYVASO/TYVASO DPI sample referral form
Secure access
Navigate access with confidence.
Our team works with you to help your patients secure and maintain access to their prescription. We’ll keep you up to date throughout the process, pull in our Therapy Access Managers as needed, and provide educational resources for your office at each stage.
Benefits investigations
Our Patient Navigators will initiate the benefits investigation process and assist patients with navigating access and affordability challenges that may arise.
Benefits investigations
Our Patient Navigators will initiate the benefits investigation process and assist patients with navigating access and affordability challenges that may arise.
Prior authorizations
Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll share materials that can help educate you through the submission process and keep you informed of your patient’s status.
Prior authorizations
Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll share materials that can help educate you through the submission process and keep you informed of your patient’s status.
Denials and appeals
If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.
Denials and appeals
If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.
Access resources
Find resources to support prior authorization, along with sample letters of medical necessity and appeals for your patients.
-
How Therapy Access Managers (TAMs) can help
-
Prior authorization checklist
-
TYVASO for PAH sample statement of medical necessity
-
TYVASO for PAH sample appeal letter
-
TYVASO for PH-ILD sample statement of medical necessity
-
TYVASO for PH-ILD sample appeal letter
-
See all resources
View all
Find financial support
Help your patient explore financial support options.
Cost is a common concern for patients. Depending on their situation, a range of financial assistance options may be available for eligible patients. We can put them in touch with our Access & Affordability Specialists to walk them through what they may qualify for.
Co-pay assistance
If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Visit our co-pay website to learn more about how eligible patients can pay as little as a $0 co-pay per prescription of TYVASO or TYVASO DPI. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to the annual maximum benefit.*
Visit co-pay site *Patients must meet certain eligibility criteria to qualify for assistance.Co-pay assistance
If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Visit our co-pay website to learn more about how eligible patients can pay as little as a $0 co-pay per prescription of TYVASO or TYVASO DPI. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to the annual maximum benefit.*
Visit co-pay site *Patients must meet certain eligibility criteria to qualify for assistance.Patient Assistance Program
If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact their Patient Navigator.
Reach outPatient Assistance Program
If patients are uninsured or underinsured, they may meet the eligibility requirements for our Patient Assistance Program (PAP). For more eligibility information, you can contact their Patient Navigator.
Reach outAdditional financial resources
Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, explore additional options through RE Assist, an online tool for finding healthcare financial support.
Visit RE AssistAdditional financial resources
Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, explore additional options through RE Assist, an online tool for finding healthcare financial support.
Visit RE Assist“The most common worry I hear is…how much is this going to cost, and how can I afford this?”

See what your patients can expect from our program.
Learn morePlease see below for Important Safety Information
WARNINGS AND PRECAUTIONS
- TYVASO and TYVASO DPI are pulmonary and systemic vasodilators. In patients with low systemic arterial pressure, either product may produce symptomatic hypotension.
- Both products inhibit platelet aggregation and increase the risk of bleeding.
IMPORTANT SAFETY INFORMATION FOR TYVASO AND TYVASO DPI
WARNINGS AND PRECAUTIONS
- TYVASO and TYVASO DPI are pulmonary and systemic vasodilators. In patients with low systemic arterial pressure, either product may produce symptomatic hypotension.
- Both products inhibit platelet aggregation and increase the risk of bleeding.
- Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.
- Like other inhaled prostaglandins, TYVASO and TYVASO DPI may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with TYVASO and TYVASO DPI.
DRUG INTERACTIONS/SPECIFIC POPULATIONS
- The concomitant use of either product with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
- Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
- Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
- Safety and effectiveness in pediatric patients have not been established.
- Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH-ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.
ADVERSE REACTIONS
-
Pulmonary Arterial Hypertension (WHO Group 1)
In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.
In a 3-week, open-label, single-sequence, safety and tolerability study (BREEZE) conducted in 51 patients on stable doses of TYVASO who switched to a corresponding dose of TYVASO DPI, the most commonly reported adverse events seen with TYVASO DPI in ≥4% of PAH patients during the 3-week treatment phase included cough (35.3%), headache (15.7%), dyspnea (7.8%), and nausea (5.9%). -
Pulmonary Hypertension Associated with ILD (WHO Group 3)
In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions with TYVASO were similar to the experience in studies of PAH.
INDICATION
TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prostacyclin mimetics indicated for the treatment of:
-
Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise
ability. Studies with TYVASO establishing effectiveness predominately
included patients with NYHA Functional Class III symptoms and etiologies
of idiopathic or heritable PAH (56%) or PAH associated with connective
tissue diseases (33%).
The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with TYVASO was limited to 12 weeks in duration. - Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with TYVASO establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).
Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI® Inhalation Powder, and additional information at www.TYVASOhcp.com or call 1-844-UNITHER (1-844-864-8437).
TYVISIhcpSEP2024









